Mater Misericordiae Hospital

AngioDynamics Initiates RECOVER-AV Trial for Pulmonary Embolism Treatment Device

- AngioDynamics has enrolled the first patient in the RECOVER-AV clinical trial, evaluating the AlphaVac F1885 System for treating intermediate-risk pulmonary embolism across multiple international sites. - The multi-center study will assess safety and long-term functional outcomes in up to 20 hospital sites across Europe, Canada, and Hong Kong, following patients for 12 months with comprehensive cardiac assessments. - The trial builds on the device's existing FDA 510(k) clearance and CE Mark approval, aiming to generate evidence for broader global adoption of mechanical thrombectomy treatment. - Pulmonary embolism affects approximately 435,000 patients annually in the six largest EU countries, representing a significant unmet medical need for effective treatment options.